茵胆平肝胶囊联合甘草酸二铵治疗慢性肝炎的临床研究

Clinical study on Yindan Pinggan Capsules combined with diammonium glycyrrhizinate in treatment of chronic hepatitis

目的分析茵胆平肝胶囊联合甘草酸二铵治疗慢性肝炎的临床效果。方法选择2017年2月-2019年4月延安市人民医院治疗的175例慢性肝炎患者,随机分为对照组(n=87)和治疗组(n=88)。对照组口服甘草酸二铵肠溶片,3片/次,3次/d。治疗组在对照组用药基础上口服茵胆平肝胶囊,2粒/次,3次/d。两组均连续治疗12周。观察两组的临床疗效,比较两组治疗前后肝功能指标、肝纤维化指标的变化情况。结果治疗后,对照组和治疗组的总有效率分别是73.56%、92.05%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组前白蛋白(PA)显著升高,但丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)和血清总胆红素(TBil)等指标均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗后治疗组患者这些肝功能指标明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗前,两组患者层粘连蛋白(LN)、透明质酸(HA)、Ⅲ型前胶原(PC-Ⅲ)水平比较,没有显著差异;与治疗前相比,治疗后两组患者LN、HA和PC-Ⅲ水平均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗后治疗组患者LN、HA和PC-Ⅲ水平显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论茵胆平肝胶囊联合甘草酸二铵片治疗慢性肝炎具有较好的临床疗效,可明显改善患者临床体征、症状,肝功能明显恢复,明显降低肝纤维化程度,具有一定的临床推广应用价值。

Objective To analyze the clinical effect of Yindan Pinggan Capsules combined with diammonium glycyrrhizinate in treatment of chronic hepatitis. Methods 175 Patients with chronic hepatitis in Yan’an people’s Hospital from February 2017 to April 2019 were randomly divided into two groups, control group(n=87) and treatment group(n=88). Patients in the control group were po administered with Diammonium Glycyrrhizinate Enteric-coated Tablets, 3 tablets/time, three times daily. Patients in the treatment group were po administered with Yindan Pinggan Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the changes of liver function indexes and liver fibrosis indexes in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 73.56% and 92.05%, respectively, and there were differences between two groups(P < 0.05). After treatment, PA was significantly increased, but ALT, AST, and TBil in two groups were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, those liver function indexes in the treatment group were significantly better than those in the control group, and there were differences between two groups(P < 0.05). After treatment, LN, HA, and PC-Ⅲ in two groups were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, those liver fibrosis indexes in the treatment group were significantly lower than those in the control group, and there were differences between two groups(P < 0.05).Conclusion Yindan Pinggan Capsules combined with diammonium glycyrrhizinate has significant effect in treatment of chronic hepatitis, and can significantly improve the clinical signs and symptoms of patients, and can significantly restore the liver function, and significantly reduce the degree of liver fibrosis, which has a certain clinical application value.